Table 2 Normative utility values for the general population (men and women)
From: Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
Age group (years) | Utility value[24] |
|---|---|
<16 | 0.91 |
16-24 | 0.91 |
25-34 | 0.91 |
35-44 | 0.88 |
45-54 | 0.85 |
55-64 | 0.79 |
65-74 | 0.78 |
≥75 | 0.73 |